Research ExplorerPublicationsUpdate Breast Cancer 2019 Part 2 - Implementation of Novel D...

Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice

Standard

Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. / Janni, Wolfgang; Schneeweiss, Andreas; Müller, Volkmar; Wöckel, Achim; Lux, Michael P; Hartkopf, Andreas D; Nabieva, Naiba; Taran, Florin-Andrei; Tesch, Hans; Overkamp, Friedrich; Lüftner, Diana; Belleville, Erik; Schütz, Florian; Fasching, Peter A; Fehm, Tanja N; Kolberg, Hans-Christian; Ettl, Johannes.

In: GEBURTSH FRAUENHEILK, Vol. 79, No. 3, 03.2019, p. 268-280.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Janni, W, Schneeweiss, A, Müller, V, Wöckel, A, Lux, MP, Hartkopf, AD, Nabieva, N, Taran, F-A, Tesch, H, Overkamp, F, Lüftner, D, Belleville, E, Schütz, F, Fasching, PA, Fehm, TN, Kolberg, H-C & Ettl, J 2019, 'Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice', GEBURTSH FRAUENHEILK, vol. 79, no. 3, pp. 268-280. https://doi.org/10.1055/a-0842-6661

APA

Janni, W., Schneeweiss, A., Müller, V., Wöckel, A., Lux, M. P., Hartkopf, A. D., Nabieva, N., Taran, F-A., Tesch, H., Overkamp, F., Lüftner, D., Belleville, E., Schütz, F., Fasching, P. A., Fehm, T. N., Kolberg, H-C., & Ettl, J. (2019). Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. GEBURTSH FRAUENHEILK, 79(3), 268-280. https://doi.org/10.1055/a-0842-6661

Vancouver

Janni W, Schneeweiss A, Müller V, Wöckel A, Lux MP, Hartkopf AD et al. Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. GEBURTSH FRAUENHEILK. 2019 Mar;79(3):268-280. https://doi.org/10.1055/a-0842-6661

Bibtex

@article{17c0d60c23d94291ba9e5b747f99a6c2,
title = "Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice",
abstract = "The treatment of patients with advanced breast cancer has developed further in recent years. In addition to therapeutic progress in the established subgroups (hormone receptor and HER2 status), there are now therapies which are geared to individual molecular characteristics, such as PARP inhibitor therapy in BRCA-mutated patients. In addition to this, tests are being developed which are intended to establish additional markers within subgroups in order to predict the efficacy of a therapy. PI3K mutation testing in HER2-negative, hormone-receptor-positive tumours and PD-L1 testing of immune cells in triple-negative tumours are expected to become established in clinical practice in order to select patients for the respective therapies. With new therapeutic approaches, new adverse effects also appear. The management of these adverse effects, just as those of classical therapy (supportive therapy), is essential with the introduction of new treatments in order to preserve patients' quality of life. Knowledge regarding measures to preserve and improve quality of life has significantly increased in recent years. Lifestyle factors should be taken into account, as should modern therapeutic methods. This review summarises the latest studies and publications and evaluates them in regard to the relevance for clinical practice.",
author = "Wolfgang Janni and Andreas Schneeweiss and Volkmar M{\"u}ller and Achim W{\"o}ckel and Lux, {Michael P} and Hartkopf, {Andreas D} and Naiba Nabieva and Florin-Andrei Taran and Hans Tesch and Friedrich Overkamp and Diana L{\"u}ftner and Erik Belleville and Florian Sch{\"u}tz and Fasching, {Peter A} and Fehm, {Tanja N} and Hans-Christian Kolberg and Johannes Ettl",
year = "2019",
month = mar,
doi = "10.1055/a-0842-6661",
language = "English",
volume = "79",
pages = "268--280",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "3",

}

RIS

TY - JOUR

T1 - Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice

AU - Janni, Wolfgang

AU - Schneeweiss, Andreas

AU - Müller, Volkmar

AU - Wöckel, Achim

AU - Lux, Michael P

AU - Hartkopf, Andreas D

AU - Nabieva, Naiba

AU - Taran, Florin-Andrei

AU - Tesch, Hans

AU - Overkamp, Friedrich

AU - Lüftner, Diana

AU - Belleville, Erik

AU - Schütz, Florian

AU - Fasching, Peter A

AU - Fehm, Tanja N

AU - Kolberg, Hans-Christian

AU - Ettl, Johannes

PY - 2019/3

Y1 - 2019/3

N2 - The treatment of patients with advanced breast cancer has developed further in recent years. In addition to therapeutic progress in the established subgroups (hormone receptor and HER2 status), there are now therapies which are geared to individual molecular characteristics, such as PARP inhibitor therapy in BRCA-mutated patients. In addition to this, tests are being developed which are intended to establish additional markers within subgroups in order to predict the efficacy of a therapy. PI3K mutation testing in HER2-negative, hormone-receptor-positive tumours and PD-L1 testing of immune cells in triple-negative tumours are expected to become established in clinical practice in order to select patients for the respective therapies. With new therapeutic approaches, new adverse effects also appear. The management of these adverse effects, just as those of classical therapy (supportive therapy), is essential with the introduction of new treatments in order to preserve patients' quality of life. Knowledge regarding measures to preserve and improve quality of life has significantly increased in recent years. Lifestyle factors should be taken into account, as should modern therapeutic methods. This review summarises the latest studies and publications and evaluates them in regard to the relevance for clinical practice.

AB - The treatment of patients with advanced breast cancer has developed further in recent years. In addition to therapeutic progress in the established subgroups (hormone receptor and HER2 status), there are now therapies which are geared to individual molecular characteristics, such as PARP inhibitor therapy in BRCA-mutated patients. In addition to this, tests are being developed which are intended to establish additional markers within subgroups in order to predict the efficacy of a therapy. PI3K mutation testing in HER2-negative, hormone-receptor-positive tumours and PD-L1 testing of immune cells in triple-negative tumours are expected to become established in clinical practice in order to select patients for the respective therapies. With new therapeutic approaches, new adverse effects also appear. The management of these adverse effects, just as those of classical therapy (supportive therapy), is essential with the introduction of new treatments in order to preserve patients' quality of life. Knowledge regarding measures to preserve and improve quality of life has significantly increased in recent years. Lifestyle factors should be taken into account, as should modern therapeutic methods. This review summarises the latest studies and publications and evaluates them in regard to the relevance for clinical practice.

U2 - 10.1055/a-0842-6661

DO - 10.1055/a-0842-6661

M3 - SCORING: Journal article

C2 - 30880825

VL - 79

SP - 268

EP - 280

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 3

ER -